WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016100308) METHODS FOR MEASUREMENT OF INHIBITION OF C-JUN N-TERMINAL KINASE IN SKIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/100308    International Application No.:    PCT/US2015/065767
Publication Date: 23.06.2016 International Filing Date: 15.12.2015
IPC:
C07D 239/48 (2006.01)
Applicants: SIGNAL PHARMACEUTICALS, LLC [US/US]; 10300 Campus Point Drive, Suite 100 San Diego, CA 92121 (US)
Inventors: HORAN, Gerald Scott, Barden; (US).
YE, Ying; (US)
Agent: BRUNER, Michael, J.; (US)
Priority Data:
62/092,531 16.12.2014 US
Title (EN) METHODS FOR MEASUREMENT OF INHIBITION OF C-JUN N-TERMINAL KINASE IN SKIN
(FR) PROCÉDÉS DE MESURE DE L'INHIBITION DE LA KINASE À TERMINAISON N C-JUN DANS LA PEAU
Abstract: front page image
(EN)Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4- ((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
(FR)La présente invention concerne des procédés d'évaluation de l'effet du 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide ou un stéréoisomère, un tautomère, une forme solide, un polymorphe, un sel, un hydrate, un clathrate ou un solvate acceptable sur le plan pharmaceutique de celui-ci chez un patient avec un dosage basé sur un rayonnement UVB et l'expression de c-Jun phosphorylé. Les analyses permettent l'évaluation de la relation dose-réponse et l'identification de populations de patients qui sont sensibles au 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide ou à un stéréoisomère, un tautomère, une forme solide, un polymorphe, un sel, un hydrate, un clathrate ou un solvate pharmaceutiquement acceptable de celui-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)